Nothing Special   »   [go: up one dir, main page]

IN2012DN05054A - - Google Patents

Download PDF

Info

Publication number
IN2012DN05054A
IN2012DN05054A IN5054DEN2012A IN2012DN05054A IN 2012DN05054 A IN2012DN05054 A IN 2012DN05054A IN 5054DEN2012 A IN5054DEN2012 A IN 5054DEN2012A IN 2012DN05054 A IN2012DN05054 A IN 2012DN05054A
Authority
IN
India
Prior art keywords
megakaryocytes
differentiation
platelets
hescs
stromal
Prior art date
Application number
Inventor
Feng Li
Shi-Jiang Lu
Original Assignee
Stem Call & Regenerative Medicine International Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Stem Call & Regenerative Medicine International Inc filed Critical Stem Call & Regenerative Medicine International Inc
Publication of IN2012DN05054A publication Critical patent/IN2012DN05054A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0644—Platelets; Megakaryocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/08—Plasma substitutes; Perfusion solutions; Dialytics or haemodialytics; Drugs for electrolytic or acid-base disorders, e.g. hypovolemic shock
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2500/00—Specific components of cell culture medium
    • C12N2500/90—Serum-free medium, which may still contain naturally-sourced components
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/10—Growth factors
    • C12N2501/115—Basic fibroblast growth factor (bFGF, FGF-2)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/10—Growth factors
    • C12N2501/125—Stem cell factor [SCF], c-kit ligand [KL]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/10—Growth factors
    • C12N2501/145—Thrombopoietin [TPO]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/10—Growth factors
    • C12N2501/155—Bone morphogenic proteins [BMP]; Osteogenins; Osteogenic factor; Bone inducing factor
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/10—Growth factors
    • C12N2501/165—Vascular endothelial growth factor [VEGF]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/23—Interleukins [IL]
    • C12N2501/2311—Interleukin-11 (IL-11)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/26—Flt-3 ligand (CD135L, flk-2 ligand)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/90—Polysaccharides
    • C12N2501/91—Heparin
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2502/00—Coculture with; Conditioned medium produced by
    • C12N2502/13—Coculture with; Conditioned medium produced by connective tissue cells; generic mesenchyme cells, e.g. so-called "embryonic fibroblasts"
    • C12N2502/1394—Bone marrow stromal cells; whole marrow
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2506/00—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells
    • C12N2506/02—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells from embryonic cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2506/00—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells
    • C12N2506/45—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells from artificially induced pluripotent stem cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Cell Biology (AREA)
  • Immunology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Diabetes (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

Abstract

The present invention provides a method of generating megakaryocytes and platelets. In various embodiments, method involves the use of human embryonic stem cell derived hemangioblasts for differentiation into megakaryocytes and platelets under serum and stromal-free condition. In this system, hESCs are directed towards megakaryocytes through embryoid body formation and hemangioblast differentiation. Further provided is a method of treating a subject in need of platelet transfusion.
IN5054DEN2012 2009-12-04 2010-12-03 IN2012DN05054A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US26693909P 2009-12-04 2009-12-04
US38416510P 2010-09-17 2010-09-17
PCT/US2010/058990 WO2011069127A1 (en) 2009-12-04 2010-12-03 Large scale generation of functional megakaryocytes and platelets from human embryonic stem cells under stromal-free conditions

Publications (1)

Publication Number Publication Date
IN2012DN05054A true IN2012DN05054A (en) 2015-10-09

Family

ID=44115332

Family Applications (1)

Application Number Title Priority Date Filing Date
IN5054DEN2012 IN2012DN05054A (en) 2009-12-04 2010-12-03

Country Status (10)

Country Link
US (2) US9988603B2 (en)
EP (1) EP2507359A4 (en)
JP (4) JP2013512676A (en)
KR (4) KR20180086301A (en)
AU (4) AU2010325811A1 (en)
BR (1) BR112012013497A2 (en)
CA (2) CA2782013C (en)
IN (1) IN2012DN05054A (en)
RU (1) RU2012127810A (en)
WO (1) WO2011069127A1 (en)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20090045886A (en) 2006-04-14 2009-05-08 어드밴스드 셀 테크놀로지, 인코포레이티드 Hemangio-colony forming cells
IN2012DN05054A (en) 2009-12-04 2015-10-09 Stem Call & Regenerative Medicine International Inc
WO2013082543A1 (en) 2011-11-30 2013-06-06 Advanced Cell Technology, Inc. Mesenchymal stromal cells and uses related thereto
GB201210857D0 (en) 2012-06-19 2012-08-01 Cambridge Entpr Ltd Transcription factor mediated programming towards megakaryocytes
EP2934555B1 (en) * 2012-12-21 2021-09-22 Astellas Institute for Regenerative Medicine Methods for production of platelets from pluripotent stem cells
JP6580329B2 (en) 2014-03-31 2019-09-25 シスメックス株式会社 Method for obtaining differentiated cells and / or products of differentiated cells from undifferentiated cells
WO2015179301A1 (en) * 2014-05-19 2015-11-26 Eleftherios Papoutsakis Megakaryocytic particles and microparticles for cell therapy & fate modification of stem and progenitor cells
AU2016242825A1 (en) * 2015-03-30 2017-09-21 Jeffrey Thomas Loh Methods for in vitro production of platelets and compositions and uses thereof
IL299326A (en) 2015-08-18 2023-02-01 Astellas Inst For Regenerative Medicine Clinical formulations
WO2017065280A1 (en) * 2015-10-14 2017-04-20 株式会社メガカリオン Method for producing purified platelets
KR102592176B1 (en) 2018-01-05 2023-10-20 플레이틀렛 바이오제네시스, 인크. Compositions and methods for generating megakaryocytes
AU2021272903A1 (en) 2020-05-11 2022-11-10 Strm.Bio Incorporated Compositions and methods related to megakaryocyte-derived extracellular vesicles

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5128259A (en) 1989-10-27 1992-07-07 Hahnemann University Factor-dependent hematopoietic cell line exhibiting epo-induced erythrocyte maturation
DE60235967D1 (en) * 2001-01-29 2010-05-27 Ivan N Rich ATP-based assay for determining the proliferation of hematopoietic stem and progenitor cells
WO2002078449A2 (en) 2001-04-02 2002-10-10 Advanced Cell Technology, Inc. Method for facilitating the production of differentiated cell types and tissues from embryonic and adult pluripotent and multipotent cells
US20030232430A1 (en) * 2001-11-26 2003-12-18 Advanced Cell Technology Methods for making and using reprogrammed human somatic cell nuclei and autologous and isogenic human stem cells
US20040052771A1 (en) 2002-07-12 2004-03-18 Lim Sai Kiang Hemangioblast progenitor cells
US20040229350A1 (en) 2003-05-12 2004-11-18 Nikolai Strelchenko Morula derived embryonic stem cells
CN1286970C (en) 2003-12-30 2006-11-29 上海伯瑞生物技术发展有限公司 Method of prodcing megacaryocyle using umbilical blood CD 344+cell in vitro induction method
US20050221482A1 (en) 2004-03-31 2005-10-06 Burt Richard K Methods and compositions for obtaining hematopoietic stem cells derived from embryonic stem cells and uses thereof
US20060099198A1 (en) 2004-11-01 2006-05-11 Thomson James A Platelets from stem cells
US7893315B2 (en) 2004-11-04 2011-02-22 Advanced Cell Technology, Inc. Derivation of embryonic stem cells and embryo-derived cells
WO2007095064A2 (en) 2006-02-09 2007-08-23 Wisconsin Alumni Research Foundation ERYTHROID CELLS PRODUCING ADULT-TYPE β-HEMOGLOBIN GENERATED FROM HUMAN EMBRYONIC STEM CELLS
CN101045914A (en) 2006-03-29 2007-10-03 中国人民解放军军事医学科学院野战输血研究所 Extracorporeal induction process for differentiating hemopoietic stem/ancestral cell into mature red blood cell and its application
KR20090045886A (en) * 2006-04-14 2009-05-08 어드밴스드 셀 테크놀로지, 인코포레이티드 Hemangio-colony forming cells
JP2008307007A (en) 2007-06-15 2008-12-25 Bayer Schering Pharma Ag Human pluripotent stem cell induced from human tissue-originated undifferentiated stem cell after birth
US9683232B2 (en) 2007-12-10 2017-06-20 Kyoto University Efficient method for nuclear reprogramming
KR20110016913A (en) 2008-05-06 2011-02-18 어드밴스드 셀 테크놀로지, 인코포레이티드 Hemangio colony forming cells and non-engrafting hemangio cells
US20110086424A1 (en) 2008-05-06 2011-04-14 Advanced Cell Technology, Inc. Methods for producing enucleated erythroid cells derived from pluripotent stem cells
IN2012DN05054A (en) 2009-12-04 2015-10-09 Stem Call & Regenerative Medicine International Inc

Also Published As

Publication number Publication date
KR20180086301A (en) 2018-07-30
US9988603B2 (en) 2018-06-05
AU2017201995B2 (en) 2019-06-06
BR112012013497A2 (en) 2016-05-31
KR20210066020A (en) 2021-06-04
US20120315338A1 (en) 2012-12-13
RU2012127810A (en) 2014-01-10
AU2019203670B2 (en) 2021-10-14
AU2019203670A1 (en) 2019-06-13
JP2013512676A (en) 2013-04-18
KR20190142424A (en) 2019-12-26
WO2011069127A1 (en) 2011-06-09
EP2507359A4 (en) 2015-05-13
AU2010325811A1 (en) 2012-06-21
JP2022064953A (en) 2022-04-26
KR20120128605A (en) 2012-11-27
EP2507359A1 (en) 2012-10-10
US20190002829A1 (en) 2019-01-03
AU2022200188A1 (en) 2022-02-10
CA2782013C (en) 2021-06-08
CA2782013A1 (en) 2011-06-09
JP2016135138A (en) 2016-07-28
CA3115233A1 (en) 2011-06-09
JP2019122385A (en) 2019-07-25
AU2017201995A1 (en) 2017-04-13

Similar Documents

Publication Publication Date Title
IN2012DN05054A (en)
PH12018501294A1 (en) Differentiation of human embryonic stem cells into pancreatic endocrine cells
GB2485112A (en) Differentiation of human embryonic stem cells
MX346002B (en) Anti-vegf antibodies and their uses.
MX2013002406A (en) Differentiation of human embryonic stem cells.
PH12016500782A1 (en) Suspension and clustering of human pluripotent stem cells for differentation into pancreatic endocrine cells
MX2015006859A (en) Anti-vegf antibodies and their uses.
EP2504425A4 (en) Differentiation of human embryonic and induced pluripotents stem cells
WO2010149597A3 (en) 3D CULTURING SYSTEMS FOR GROWTH AND DIFFERENTIATION OF HUMAN PLURIPOTENT STEM (hPS) CELLS
NZ602808A (en) Angiogenesis using placental stem cells
JO3182B1 (en) High Affinity Human Antibodies to Human Angiopoietin-2
AU341133S (en) Carburetor main body
WO2011130675A3 (en) Dopaminergic neurons differentiated from pluripotent stem cells and uses of thereof
TWD155721S (en) Bottle
MX2013002405A (en) Differentiation of human embryonic stem cells.
MX2013010557A (en) Human tissue factor antibody and uses thereof.
MX2013006595A (en) Treatment of spinal cord injury and traumatic brain injury using placental stem cells.
MX340253B (en) Surgical needle coating and methods.
AU336556S (en) Laser system for treatment of the eye
TWD146687S (en) Implantable blood pump
PH12014501426A1 (en) Induced pluripotent stem cells from human umbilical cord tissue-derived cells
IN2014KN02364A (en)
AU336555S (en) Laser system for treatment of the eye
PT2516406E (en) Mglu2 agonists
MX336198B (en) Surgical needle coatings and methods.